Accelerate your CDMO or DTC pipeline. Map the exact physiochemical constraints, bioavailability synergies, and optimal delivery mechanisms for Lacto-N-tetraose.
A core human milk oligosaccharide (HMO) that acts as a selective prebiotic substrate for Bifidobacterium species, modulating gut microbiota composition and supporting neonatal immune system maturation.
123831
202.25 g/mol
-3.6
(2S)-2-amino-5-[[amino(dimethylamino)methylidene]amino]pentanoic acid
Every active compound behaves uniquely based on the physical matrix it is suspended in. Below are the known physical chemistry challenges for Lacto-N-tetraose across standard consumer modalities.
The hygroscopic nature of the amorphous powder requires moisture-barrier packaging to prevent clumping and maintain long-term stability.
High solubility and thermal stability allow for easy integration, though high inclusion levels may disrupt pectin gel networks and increase water activity.
Standard therapeutic dosages for HMOs typically exceed the 50mg payload capacity of thin-film polymer matrices, making this format impractical for primary dosing.
Ready to launch a product featuring Lacto-N-tetraose? Skip months of expensive wet-lab iterations. Generate a manufacturer-ready formulation in hours, instantly screened for physical incompatibilities and global regulatory compliance.
Build Science-Backed FormulationNeed absolute proof that your Lacto-N-tetraose extract actually absorbs? Stop blindly combining generic powders. Run a physics-based PBPK simulation to mathematically engineer peak clinical efficacy and targeted plasma concentrations.
Simulate BioavailabilityIs your Lacto-N-tetraose payload degrading in the capsule before the expiration date? Stop waiting for costly bench testing. Run an accelerated digital twin to precisely model oxidation pathways and pH shifts before finalizing a manufacturing run.
Model Active Degradation